A 5-Year Prospective Observational Study of the Outcomes of International Treatment Guidelines for Crohn's Disease

Clinical Gastroenterology and Hepatology

Volumn 7, Issue 3, 2009, Pages 323-328

  Cullen, Garret ^a   Keegan, Denise ^a   Mulcahy, Hugh E ^a   O'Donoghue, Diarmuid P ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AMINOSALICYLIC ACID DERIVATIVE; ANTIBIOTIC AGENT; AZATHIOPRINE; CORTICOSTEROID; HYDROCORTISONE; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC THERAPY; ANUS DISEASE; ARTHROPATHY; ARTICLE; CHRONOTHERAPY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CROHN DISEASE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG UTILIZATION; DRUG WITHDRAWAL; ENTEROCUTANEOUS FISTULA; FEMALE; FOLLOW UP; HUMAN; IMMUNOMODULATION; INTESTINE FISTULA; INTESTINE RESECTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PARENTERAL NUTRITION; PRACTICE GUIDELINE; PROSPECTIVE STUDY; REMISSION; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SEPSIS; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CASE MANAGEMENT; CROHN DISEASE; FEMALE; FOLLOW-UP STUDIES; GUIDELINES AS TOPIC; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 60949094954     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2008.10.018     Document Type: Article

References (18)

1. Lichtenstein G.R., Abreu M.T., Cohen R., et al. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 130 (2006) 935-939
2. Travis S.P., Stange E.F., Lemann M., et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 55 Suppl 1 (2006) i16-i35
3. D'Haens G., Baert F., van Assche G., et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 371 (2008) 660-667
4. Faubion Jr. W.A., Loftus Jr. E.V., Harmsen W.S., et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 121 (2001) 255-260
5. Lichtenstein G.R., Feagan B.G., Cohen R.D., et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 4 (2006) 621-630
6. Aberra F.N., and Lichtenstein G.R. Methods to avoid infections in patients with inflammatory bowel disease. Inflamm Bowel Dis 11 (2005) 685-695
7. Munkholm P., Langholz E., Davidsen M., et al. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 35 (1994) 360-362
8. Colombel J.F., Loftus Jr. E.V., Tremaine W.J., et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 126 (2004) 19-31
9. Ljung T., Karlen P., Schmidt D., et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 53 (2004) 849-853
10. Harvey R.F., and Bradshaw J.M. A simple index of Crohn's-disease activity. Lancet 1 (1980) 514
11. Silverberg M.S., Satsangi J., Ahmad T., et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 19 Suppl A (2005) 5-36
12. Johnson F.R., Ozdemir S., Mansfield C., et al. Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy. Gastroenterology 133 (2007) 769-779
13. Cullen G., O'Toole A., Keegan D., et al. Long-term clinical results of ileocecal resection for Crohn's disease. Inflamm Bowel Dis 13 (2007) 1369-1373
14. Solberg I.C., Vatn M.H., Hoie O., et al. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol 5 (2007) 1430-1438
15. Cosnes J., Cattan S., Blain A., et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 8 (2002) 244-250
16. Louis E., Collard A., Oger A.F., et al. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut 49 (2001) 777-782
17. Eisen G.M. Endoscopic databases and outcomes research. Gastrointest Endosc Clin N Am 9 (1999) 587-594 vi
18. Hogan W.R., and Wagner M.M. Accuracy of data in computer-based patient records. J Am Med Inform Assoc 4 (1997) 342-355